Precision treatments company DalCor Pharmaceuticals revealed on Wednesday the addition of Fouzia Laghrissi-Thode to its board of directors.

Currently, Dr Laghrissi-Thode serves as vice-president at AstraZeneca, leading the US Renal-Cardiology Therapeutic Area based in San Francisco as well as led the Global Cardiovascular Metabolism Therapeutic Area.

Previously, Dr.Laghrissi-Thode has worked with Novartis, Sandoz and Roche in clinical development, global strategic marketing, business development and licensing in therapeutic areas including diabetes, renal and the central nervous system as well as engaged in the development of Dalcetrapib and the Dal-HEART programme at Roche.

Earlier in her career, Dr Laghrissi-Thode was a board member of the Healthcare Businesswomen's Association (HBA) Europe and was recognized by HBA in 2012 for her work in developing and promoting women leadership in healthcare.